Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could donated fat ease your knee pain? new trial underway

NCT ID NCT06828666

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 2 times

Summary

This study tests a new treatment called BRC-OA, made from donated human fat tissue, for people with mild to severe knee osteoarthritis. The goal is to see if it safely reduces pain and improves knee function. About 42 adults aged 18-80 will receive one of two doses or a control, and be followed for 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

46 people

The number who actually took part.

Started

May 2025

Finished

Aug 2026

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males or females 18-80 years of age, inclusive 2. Diagnosis of OA in one or both knees supported by documentation of clinical and radiographic findings(KL Grades 2-4) up to 6 months prior to screening: 1. Diagnosis of degenerative or post-traumatic OA of the knee supported by documentation of clinical and radiographic findings up to 6 months prior to screening 2. Degenerative meniscal tears allowed as long as there are no pending surgeries 3. Flexion Contraction and Valgus/Varus deformity allowed if \< 10 degrees 3. Subject must have tried for at least 3 months and failed on at least two of the following pharmacological standard of care therapies in the past 12 months: 1. Acetaminophen 2. NSAID (e.g., ibuprofen, naproxen) 3. Opioid (e.g., tramadol) 4. Topical NSAID (e.g., diclofenac gel) 5. Intra-articular injections (e.g., corticosteroids, hyaluronic acid) 4. Subjects knee pain persists for at least 12 weeks prior to screening and does not improve with pain medications (e.g., NSAIDs, acetaminophen, tramadol, etc.) and/or other nonoperative treatment options 5. Index knee WOMAC pain subscale score of ≥ 40 on a normalized/standardized scale of 0 to 100 at screening visit Note: The index knee in subjects with bilateral OA of the knees is the one with worse pain with walking. Where both knees have equal pain with walking, then the knee on the subject's dominant side will be designated the index knee. Exclusion Criteria: 1. BMI greater than 40 kg/m2 2. Previous IA injections (e.g., corticosteroid, hyaluronic acid (HA), platelet rich plasma (PRP), etc.) into the index knee within 3 months prior to screening 3. Prior Partial Joint Replacement (PJR) or Total Joint Replacement (TJR) of one or both knees 4. Knee surgery in the previous 6 months prior to enrollment and/or planned knee surgery during the study 5. Symptomatic OA of the hips, spine, or ankle that would interfere with the evaluation of the treated knee 6. Rapidly progressing osteoarthritis (RPOA) 7. Prior cartilage transplants in the index knee 8. Subjects who are actively treated with oral anticoagulants or heparin therapy (treatment such as low dose Aspirin and Plavix are allowed) 9. Current therapy with any immunosuppressive therapy, including corticosteroids (\> 5mg/day of prednisone) 10. Any method of medical marijuana use containing THC or CBD, including smoke or vaporized spray inhalation, pills or liquids, edible foods, topical applications, etc. 11. Clinically significant intercurrent illness, medical condition, non-knee pain, or medical history that could jeopardize the patient safety, limit participation, or compromise interpretation of data derived from the patient; this includes neurological or mental illness, human immunodeficiency virus, fibromyalgia, complex regional pain syndrome, or any active infection - including hepatitis B or C 12. Active alcohol or substance use disorder, or any other reason that would make it unlikely for the patient to comply with study procedures 13. Females who are lactating or pregnant (positive pregnancy test for females of childbearing potential at screening Females of childbearing potential must be willing to use an acceptable method of contraception from screening up until 90 days after study drug injection administration Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, patch, injectable, depot, or vaginal) in conjunction with a barrier method (e.g., diaphragm, cervical cap, condom, spermicide, or sponge), or female subject/partner's use of an implantable device (implantable rod or intrauterine device) 14. Subject has known allergy to any components of BRC-OA 15. Subject has received an investigational product within 3 months before screening 16. Any medical condition, which in the opinion of the clinical investigator, would interfere with the treatment or outcome of the patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis of knee are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Elevate Clinical Research

    Rockville, Maryland, 20874, United States

  • LifeBridge Health

    Baltimore, Maryland, 21215, United States

  • MD Medical Research

    Oxon Hill, Maryland, 20745, United States

  • Northwell Health

    New York, New York, 10065, United States

  • The Osteoporosis & Clinical Trials Center

    Hagerstown, Maryland, 21740, United States

  • University Orthopedics Center

    Altoona, Pennsylvania, 16602, United States

  • University Orthopedics Center

    State College, Pennsylvania, 16801, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.